{"title":"Dapagliflozin: a new possibility for managing type 2 diabetes","authors":"Stephen Bain MA, MD, FRCP","doi":"10.1002/fps.86","DOIUrl":null,"url":null,"abstract":"<p><b>Dapagliflozin is a new sodium-glucose transporter protein inhibitor under development for the treatment of type 2 diabetes mellitus. In this Drug profile, Professor Stephen Bain outlines why new treatments are needed, and considers the drug's efficacy and tolerability in clinical trials, to date, as well as its potential place in management.</b> Copyright © 2011 John Wiley & Sons, Ltd.</p>","PeriodicalId":100566,"journal":{"name":"Future Prescriber","volume":"12 4","pages":"14-16"},"PeriodicalIF":0.0000,"publicationDate":"2012-01-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1002/fps.86","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Future Prescriber","FirstCategoryId":"1085","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/fps.86","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
Dapagliflozin is a new sodium-glucose transporter protein inhibitor under development for the treatment of type 2 diabetes mellitus. In this Drug profile, Professor Stephen Bain outlines why new treatments are needed, and considers the drug's efficacy and tolerability in clinical trials, to date, as well as its potential place in management. Copyright © 2011 John Wiley & Sons, Ltd.
达格列净:治疗2型糖尿病的新可能性
达格列净是一种用于治疗2型糖尿病的新型钠-葡萄糖转运蛋白抑制剂。在这篇药物简介中，Stephen Bain教授概述了为什么需要新的治疗方法，并考虑了迄今为止该药物在临床试验中的疗效和耐受性，以及它在治疗中的潜在地位。版权所有©2011 John Wiley &儿子,有限公司
本文章由计算机程序翻译，如有差异，请以英文原文为准。
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
